OptiBiotix Health (OPTI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

17.75p
   
  • Change Today:
    -0.25p
  • 52 Week High: 39.00
  • 52 Week Low: 6.00
  • Currency: UK Pounds
  • Shares Issued: 97.94m
  • Volume: 11,295
  • Market Cap: £17.38m

OptiBiotix strikes LPLDL food supplement deal in Japan

By Josh White

Date: Wednesday 03 Jul 2019

LONDON (ShareCast) - (Sharecast News) - Life sciences company OptiBiotix Health announced on Wednesday that its fully-owned subsidiary ProBiotix Health has signed a non-exclusive license agreement with Tenshindo for the use of lactobacillus plantarum 'LPLDL' in cardiovascular food supplements in Japan.
The AIM-traded firm said Tenshindo is a manufacturer of functional food and cosmetics products, founded in Japan in 1986.

It said LPLDL would be the active ingredient in a "novel" cardiovascular health product, that Tenshindo would add to its current portfolio of more than 50 products.

Tenshindo and ProBiotix would work together to obtain an authorised cardiovascular health claim for LPLDL from the Japanese authorities, based on the existing clinical and market evidence on the strain.

OptiBiotix said it was the first end product application deal in Japan emerging from ProBiotix's agreement with the local distributor EIWA Trading Corporation in February, to distribute LPLDL in the country, and part of its strategy to include LPLDL in a wide range of cardiovascular health supplements, and in food, dairy, and beverage products globally.

EIWA and ProBiotix were said to be working together to replicate that model with different partners and different applications in the Japanese market.

"We are pleased to announce this deal with Tenshindo, which will mean our first LPLDL finished product placement on the Japanese market," said OptiBiotix Health business development director Dr Luis Gosalbez.

"Obtaining an authorised cardiovascular health claim for LPLDL from Japanese authorities will not only be highly advantageous from the commercial point of view, but also an important endorsement for ProBiotix's science.

"Tenshindo, with over 30 years of experience in this market, are an excellent commercial and regulatory partner to make the most of this opportunity."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OPTI Market Data

Currency UK Pounds
Share Price 17.75p
Change Today -0.25p
% Change -1.39 %
52 Week High 39.00
52 Week Low 6.00
Volume 11,295
Shares Issued 97.94m
Market Cap £17.38m

OPTI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
60.16% above the market average60.16% above the market average60.16% above the market average60.16% above the market average60.16% above the market average
92.16% above the sector average92.16% above the sector average92.16% above the sector average92.16% above the sector average92.16% above the sector average
Price Trend
16.42% below the market average16.42% below the market average16.42% below the market average16.42% below the market average16.42% below the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Income Not Available
Growth
96.72% below the market average96.72% below the market average96.72% below the market average96.72% below the market average96.72% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

OPTI Dividends

No dividends found

Trades for 14-May-2024

Time Volume / Share Price
12:46 200 @ 18.00p
11:06 3,631 @ 17.70p
11:00 1,464 @ 17.50p
11:00 1,464 @ 17.50p
09:24 1,000 @ 17.69p

OPTI Key Personnel

CEO Stephen O'Hara
Finance Director Graham Myers

Top of Page